Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Cspc Zhongqi Pharmaceutical Technology (shijiazhuang) Co., Ltd.

Shandong Danhong Pharmaceutical Co., Ltd.

Fujian Akeylink Biotechnology Co., Ltd.

Jiahu Wu

Chengde Wu

Tao Yu

Ning Li

Chunli Shen

Ting Wang

Shuhui Chen

Yong Liu

Yong Wang

Zheng Wang

Lin Zhang

Feng Guo

Wentao Wu

Fei Liu

Xin Tian

Bing Deng

Zhixiang Li

Changjun Wang

Zongbin Li

Shenglin Chen

Lingwei Kong

Zhemin Rong

Peipei Jiang

Shengbin Zhang

Yusheng Fu

Huanyu Bian

Yuing Guo

The present application belongs to the field of medicine, and in particular relates to a crystal of a diarylthiohydantoin compound, a preparation method therefor, and use thereof in the preparation of medicaments for treating related diseases which are androgen-mediated.

Crystal of diarylthiohydantoin compound

Disclosed are a solid form and a crystal form of a compound represented by formula (I) used as a BRD4 inhibitor, a preparation method therefor, and an application thereof in the preparation of a medicine for treating BRD4-related diseases. (I).

BRD4 inhibitor compound in solid form and preparation method therefor and use thereof

Provided are crystal forms A, B, C and D of a compound of formula (I), and application of the crystal forms in the preparation of drugs for treating ASK1-related diseases.

Crystal form as ASK1 inhibitor and preparation method and application thereof

Disclosed are a sustained release suspension containing dezocine analogue ester and a preparation method therefor. According to the present invention, an injectable oily auxiliary material which may pharmaceutically serve as a sustained-release depot and an excipient are selected, and micronization technology is used jointly with high pressure homogenization technology and an anti-solvent technique to prepare an injectable long-acting suspension. The main components of the suspension are a compound represented by formula (I), the injectable oil, and the like. 

Sustained release suspension containing dezocine analogue ester and preparation method therefor

Disclosed in the present invention are a crystalline Form of pyrido[1,2-a]pyrimidone analog, a preparation method therefor and an intermediate thereof. 

Pyrido[1,2-A]pyrimidone analog, crystal form thereof, intermediate thereof and preparation method therefor

Growing community of inventors

Shanghai, China

Jiahu Wu